Viewing StudyNCT05203445



Ignite Creation Date: 2024-05-06 @ 5:07 PM
Last Modification Date: 2024-10-26 @ 2:22 PM
Study NCT ID: NCT05203445
Status: RECRUITING
Last Update Posted: 2024-01-25
First Post: 2022-01-10

Brief Title: A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer TNBC or Hormone Receptor-positive HER2-negative Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Organization: Memorial Sloan Kettering Cancer Center

Conditions & Keywords Data

Conditions:
Name
Breast Cancer
Keywords:
Name View
21-018 View
Stage T1c-3N0-3 View
Olaparib View
Pembrolizumab View